JASCAYD vs OFEV for Pulmonary Sarcoidosis: Treatment Recommendation
Neither JASCAYD (nerandomilast) nor OFEV (nintedanib) should be used as standard therapy for progressive pulmonary sarcoidosis, as current guidelines do not support antifibrotic agents for this indication. Instead, follow the established treatment algorithm: corticosteroids as first-line, methotrexate as second-line steroid-sparing agent, and infliximab as third-line for refractory disease 1, 2.
Why Antifibrotics Are Not Recommended for Sarcoidosis
The evidence base is clear on this point:
JASCAYD is FDA-approved only for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) 3. Sarcoidosis is explicitly not included in its approved indications.
OFEV (nintedanib) has no evidence supporting its use in sarcoidosis. The 2024 ACR/CHEST guidelines conditionally recommend against nintedanib for most systemic autoimmune rheumatic disease-associated ILD (SARD-ILD), and sarcoidosis is not a SARD 4.
Sarcoidosis is fundamentally an inflammatory granulomatous disease, not a primary fibrotic process like IPF. While up to 20% of sarcoidosis patients develop fibrosis, this occurs as a consequence of chronic inflammation 5, 6. The pathophysiology differs fundamentally from IPF, where antifibrotics have proven efficacy.
The Evidence-Based Treatment Algorithm for Progressive Pulmonary Sarcoidosis
The 2020 Delphi consensus and 2021 ERS guidelines provide clear direction 1, 2:
First-Line: Corticosteroids
- Prednisone 20-40 mg daily for 3-6 months for symptomatic or organ-threatening disease
- Taper to the lowest effective dose
- Do NOT use in asymptomatic patients—nearly half never require systemic treatment 1
Second-Line: Add Methotrexate
Add when:
- Disease progression despite corticosteroids
- Steroid toxicity (weight gain, metabolic complications, reduced quality of life)
- Need for prolonged therapy (>6 months)
Methotrexate is the most widely studied and best-tolerated second-line agent with placebo-controlled trial evidence 1, 2. Alternatives that did not reach consensus include azathioprine, mycophenolate, and leflunomide 1.
Third-Line: Add Infliximab
Add when:
- Insufficient response to methotrexate plus corticosteroids
- Severe or progressive disease
- Toxicity from other agents
Infliximab is the preferred biologic with multiple clinical trials supporting its use in various sarcoidosis manifestations, including two phase III trials showing improved FVC and quality of life 1, 2. Adalimumab is an alternative, but other anti-TNF agents (golimumab, etanercept) are ineffective 1.
Why the Question About Antifibrotics Arises (And Why It's Premature)
Recent theoretical interest exists because:
Nintedanib showed benefit in the INBUILD trial for progressive fibrosing ILD (PF-ILD), which included a small subset of sarcoidosis patients 7. However, this was not powered to assess sarcoidosis specifically.
Real-world data on nintedanib in non-IPF PPF shows attenuated FVC decline (-72 to -89 mL/year on treatment vs -188 to -240 mL/year pre-treatment), but these are uncontrolled pre-post analyses with very low certainty of evidence 8.
JASCAYD (nerandomilast) is newly approved (October 2025) for IPF and PPF based on FIBRONEER trials showing reduced FVC decline 3, 9, 10, 11. However, the PPF indication specifically excluded patients on high-dose immunosuppression (>15 mg prednisone) and those recently treated with mycophenolate, rituximab, or cyclophosphamide 3—the very agents used in sarcoidosis.
Critical Pitfalls to Avoid
Do not confuse "progressive pulmonary fibrosis" with "fibrotic sarcoidosis." PPF as defined in clinical trials refers to specific non-IPF ILDs meeting progression criteria, and sarcoidosis was either excluded or represented a tiny minority 3, 8.
Do not skip immunosuppression. Sarcoidosis fibrosis develops from chronic inflammation. Treating with antifibrotics alone ignores the underlying inflammatory process 5, 6.
Do not use prolonged corticosteroid monotherapy. This outdated approach causes significant toxicity without adequately addressing disease progression 1.
Consider pneumocystis prophylaxis when using ≥20 mg prednisone with a cytotoxic agent for >6 months 1.
When to Consider Lung Transplantation
Refer patients with refractory disease not responding to the full treatment algorithm (corticosteroids → methotrexate → infliximab) for transplant evaluation 4, 6. Refractory disease is defined as progressive disease despite ≥10 mg prednisolone for ≥3 months requiring additional disease-modifying agents, with significant impairment of life from progressive pulmonary symptoms 6.
Future Directions
While antifibrotics like nintedanib and nerandomilast "might hold promise" for pulmonary fibrosis in sarcoidosis 5, 6, randomized controlled trials are essential before clinical use can be recommended. Current evidence is theoretical or extrapolated from other ILD populations. Until such trials exist, stick to the proven immunosuppressive algorithm.